Search Result

Results for "

MDM2 Inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Apoptosis (33) Autophagy (6) Bcl-2 Family (1) c-Myc (2) CDK (2) COX (1) Cyclophilin (1) Deubiquitinase (6) Dihydroorotate Dehydrogenase (1) DNA Methyltransferase (1) Drug Intermediate (1) Drug Isomer (2) Drug-Linker Conjugates for ADC (1) E1/E2/E3 Enzyme (36) Epigenetic Reader Domain (1) Ferroptosis (1) Fungal (3) HDAC (3) Histone Methyltransferase (1) IAP (2) Interleukin Related (1) Isotope-Labeled Compounds (4) Ligands for E3 Ligase (3) Ligands for Target Protein for PROTAC (1) Lipoxygenase (1) LPL Receptor (1) MAGL (1) MDM-2/p53 (109) NF-κB (2) Parasite (1) PARP (1) PDK-1 (1) PROTACs (7) PTEN (1) Reactive Oxygen Species (ROS) (1) Sirtuin (1) TNF Receptor (1) Wnt (1) β-catenin (2)
By Research Areas:	Cancer (126) Cardiovascular Disease (2) Endocrinology (1) Infection (3) Inflammation/Immunology (5) Neurological Disease (2)

By Targets:

Akt (2)

Apoptosis (33)

Autophagy (6)

Bcl-2 Family (1)

c-Myc (2)

CDK (2)

COX (1)

Cyclophilin (1)

Deubiquitinase (6)

Dihydroorotate Dehydrogenase (1)

DNA Methyltransferase (1)

Drug Intermediate (1)

Drug Isomer (2)

Drug-Linker Conjugates for ADC (1)

E1/E2/E3 Enzyme (36)

Epigenetic Reader Domain (1)

Ferroptosis (1)

Fungal (3)

HDAC (3)

Histone Methyltransferase (1)

IAP (2)

Interleukin Related (1)

Isotope-Labeled Compounds (4)

Ligands for E3 Ligase (3)

Ligands for Target Protein for PROTAC (1)

Lipoxygenase (1)

LPL Receptor (1)

MAGL (1)

MDM-2/p53 (109)

NF-κB (2)

Parasite (1)

PARP (1)

PDK-1 (1)

PROTACs (7)

PTEN (1)

Reactive Oxygen Species (ROS) (1)

Sirtuin (1)

TNF Receptor (1)

Wnt (1)

β-catenin (2)

By Research Areas:

Cancer (126)

Cardiovascular Disease (2)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (5)

Neurological Disease (2)

129

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-70027A

*p53 and MDM2* proteins-interaction-inhibitor dihydrochloride**	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-70027

*p53 and MDM2* proteins-interaction-inhibitor (chiral)**	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor (chiral) (Compound 32) is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-128842

PROTAC MDM2 Degrader-3	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-3 is a *MDM2* degrader based on PROTAC technology. PROTAC MDM2 Degrader-3 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase .

HY-130684

MDM2-IN-1	MDM-2/p53	Cancer
MDM2-IN-1 (Compound 30) is a synthetic **MDM2-p53 interaction (MDM2)** inhibitor and contains the trans (D-)configuration .

HY-70028

*p53 and MDM2* proteins-interaction-inhibitor (racemic)**	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53 and MDM2 proteins-interaction-inhibitor (racemic) (Compound 2j) is an inhibitor of the interaction between p53 and MDM2 proteins.

HY-162035

MDM2-IN-23	MDM-2/p53	Cancer
MDM2-IN-23 (compound 5d) is an inhibitor of MDM2. MDM2-IN-23 has an IC₅₀ of 60.09 μM on MCF-7 cells .

HY-163357

CDK2/MDM2-IN-1	CDK MDM-2/p53	Cancer
CDK2/MDM2-IN-1 (III-13) is a dual inhibitor of CDK2/MDM2 with an IC₅₀ value of 2.60 nM for CDK2. CDK2/MDM2-IN-1 has antitumor activity .

HY-139458

MDM2-IN-21	MDM-2/p53	Cancer
MDM2-IN-21 is a potent *MDM2* inhibitor. MDM2-IN-21 can be used for the research of cancer .

HY-128843

PROTAC MDM2 Degrader-4	PROTACs MDM-2/p53 E1/E2/E3 Enzyme	Cancer
PROTAC MDM2 Degrader-4 is a *MDM2* degrader based on PROTAC technology. PROTAC MDM2 Degrader-4 composes of a potent MDM2 inhibitor, linker, and the MDM2 ligand for E3 ubiquitin ligase .

HY-162247

MDM2-IN-26	MDM-2/p53	Cancer
MDM2-IN-26 (compound A3) is an *MDM2* inhibitor that can activate the tumor suppressor function of p53 by blocking the interaction between MDM2 and p53 (MDM2 is the main negative regulator of p53). MDM2-IN-26 can be used for cancer research .

HY-149250

MDMX/MDM2-IN-2	MDM-2/p53 Apoptosis	Cancer
MDMX/MDM2-IN-2 is a potent *p53-MDM2/MDMX* dual inhibitors with K_is of 0.23 μM and 2.45 μM for MDM2 and MDMX, respectively. MDMX/MDM2-IN-2 inhibits the binding of p53 and MDM2 proteins. MDMX/MDM2-IN-2 restores the function of p53 and enables cell cycle arrest and apoptosis. MDMX/MDM2-IN-2 inhibits cell migration and invasion. MDMX/MDM2-IN-2 has antitumor activity .

HY-153200

MDM2/XIAP-IN-2	MDM-2/p53	Cancer
MDM2/XIAP-IN-2 is a dual inhibitor of murine double minute 2 (MDM2) and *X-linked inhibitor* of apoptosis protein (XIAP*). MDM2/XIAP-IN-2 degrades MDM2, and inhibits* XIAP mRNA translation to inhibits cancer cells. Particularly, MDM2/XIAP-IN-2 inhibits acute lymphoblastic leukemia cell line EU-1 with an IC₅₀ value of 0.3 μM .

HY-14967

NSC 66811	MDM-2/p53	Cancer
NSC 66811 is a *MDM2-p53* inhibitor, with a K_i of 120 nM for binding to MDM2 .

HY-151172

MDM2-p53-IN-15	MDM-2/p53 Apoptosis	Cancer
MDM2-p53-IN-15 is a *MDM2-p53* inhibitor with an IC₅₀ value of 26.1 nM. MDM2-p53-IN-15 inhibits the proliferation of various cancer cells and induces cell apoptosis. MDM2-p53-IN-15 can be used for the research of cancer .

HY-148833

MDM2-p53-IN-16	MDM-2/p53	Cancer
MDM2-p53-IN-16 is a *MDM2-p53* complex inhibitor with an IC₅₀ value of 4.3 nM to dissociate human p53/MDM2 complex. MDM2-p53-IN-16 reactivates p53, and induces Glioblastoma Multiforme (GBM) cell apoptosis and cell-cycle arrest. MDM2-p53-IN-16 can be used for the cancer research .

HY-148106

MEL23	Ligands for E3 Ligase	Cancer
MEL23 is a MDM2 E3 ligase inhibitor that blocks the E3 ligase activity of the MDM2-MDMX complex. MEL23 inhibits Mdm2 and p53 ubiquitination in cells, reduce viability of cells with wild-type p53. MEL23 stabilizes MDM2 via a mechanism independent of p53 transcription .

HY-163661

p53-MDM2-IN-5	Apoptosis Autophagy MDM-2/p53	Cancer
p53-MDM2-IN-5 (compound 5a) is a potent *p53-MDM2* inhibitor. p53-MDM2-IN-5 induces apoptosis, autophagy and DNA damage. p53-MDM2-IN-5 induces cell cycle arrest at S and G2/M phases. p53-MDM2-IN-5 shows anti-tumor activity .

HY-15676

Idasanutlin 40+ Cited Publications RG7388	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Idasanutlin (RG7388) is a potent and selective *MDM2* antagonist, inhibiting p53-MDM2 binding, with an IC₅₀ of 6 nM.

HY-168606A

p53-MDM2-IN-7 hydrochloride	MDM-2/p53	Cancer
p53-MDM2-IN-7 (compound 6d) (hydrochloride) is a *p53-MDM2* inhibitor. p53-MDM2-IN-7 has an IC₅₀ value of 8.13 μM against A549 cells. p53-MDM2-IN-7 can be used in anti-cancer research .

HY-121893

p53-MDM2-IN-3	MDM-2/p53 NF-κB	Cancer
p53-MDM2-IN-3 (Compound 5s) is an orally active *p53-MDM2* inhibitor with a K_i value of 0.25 μM. p53-MDM2-IN-3 exerts antitumor activity by inhibiting NF-κB pathway .

HY-116052

p53-MDM2-IN-2	MDM-2/p53 NF-κB	Cancer
p53-MDM2-IN-2 (Compound 5q) is an orally active *p53-MDM2* inhibitor with a K_i value of 0.25 μM. p53-MDM2-IN-2 exerts antitumor activity by inhibiting NF-κB pathway .

HY-153199

MDM2/XIAP-IN-1	MDM-2/p53 IAP	Cancer
MDM2/XIAP-IN-1 (compound 14) is an orally active inhibitor of dual MDM2/XIAP. MDM2/XIAP-IN-1 has anti-cancer activity with an IC₅₀ value of 0.3 μM, which can be used in cance rescrch .

HY-162927

p53-MDM2-IN-6	MDM-2/p53 Apoptosis	Cancer
p53-MDM2-IN-6 (Compound 10a), a LSM-83177 hydrazone analog, is a potent *p53-MDM2* inhibitor with an IC₅₀ value of 11.08 µg/mL. p53-MDM2-IN-6 arrests the cell cycle in the S phase and induces early and late Apoptosis with antiproliferative activity against HT29 cell lines with an IC₅₀ value of 10.44 µg/mL. p53-MDM2-IN-6 inhibits p53-MDM2 interaction with increment in p-53 level and decrease the expression of GST enzymes. p53-MDM2-IN-6 is promising for research of colorectal cancer .

HY-W340839

p53-MDM2-IN-1	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-1 (Example 30) is an inhibitor of *p53-MDM2/X* protein interaction with an K_i value of 23.35 µM. p53-MDM2-IN-1 can be used for anti-tumor research .

HY-W340313

p53-MDM2-IN-4	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
p53-MDM2-IN-4 (Example 4) is an inhibitor of *p53-MDM2/X* protein interaction, with a K_i value of 3.079 μM. p53-MDM2-IN-4 can be used in anti-tumor research .

HY-161039

MDM2-p53-IN-18	MDM-2/p53	Cancer
MDM2-p53-IN-18 (Compd A-7b) is a *MDM2-p53* interaction inhibitor .

HY-164550

YF438	HDAC	Cancer
YF438 is an HDAC inhibitor with effective anticancer activity both in vitro and in vivo. YF438 inhibits the growth and metastasis of triple-negative breast cancer (TNBC) cells by blocking the interaction between HDAC and *MDM2, inducing the dissociation of MDM2-MDMX, and promoting the degradation of MDM2* .

HY-163275

MDM2-IN-24	MDM-2/p53 Apoptosis	Cancer
MDM2-IN-24 (compound A3f) exhibits *MDM2*-inhibiting and MDMX-activating properties in triple-negative breast cancer (TNBC) cells, with apoptotic and anti-proliferative activities .

HY-18052

AM-8553	MDM-2/p53	Cancer
AM-8553 is a *MDM2/p53* inhibitor (K_D: 0.4 nM for MDM2). AM-8553 has anti-tumor activity

HY-158685

RG7112D	MDM-2/p53	Cancer
RG7112D is a potent *MDM2* inhibitor with IC₅₀s of 11 nM and >10000 nM and for MDM2-p53 and VHL-HIF1α by binding HTRF assay, respectively. RG7112D is coupled by an amide bond to VHL-Amine, resulting in a bi-functional molecule, YX-02-030. YX-02-03, a MDM2-PROTAC, potently inhibits MDM2-p53 binding (HTRF IC₅₀=63nM). RG7112D can stabilize MDM2 protein and increase p53 protein levels .

HY-161041

MDM2-p53-IN-20	MDM-2/p53	Cancer
MDM2-p53-IN-20 (Compd B-11j) is a synthetic *MDM2-p53* interaction inhibitor that play an important role in cancer .

HY-10959

RG7112 15+ Cited Publications RO5045337	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
RG7112 is a potent, selective, first clinical, orally active and blood-brain barrier crossed *MDM2-p53* inhibitor, with an IC₅₀ of 18 nM and a K_D of 11 nM for binding to MDM2 .

HY-12296

Navtemadlin 20+ Cited Publications AMG 232; KRT-232	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of *p53-MDM2* interaction, with an IC₅₀ of 0.6 nM. Navtemadlin binds to MDM2 with a K_d of 0.045 nM .

HY-107466

WK298	MDM-2/p53	Cancer
WK298 is a potent inhibitor of the MDM2/MDMX-p53 interaction with good anti-tumor activity. WK298 can fully activate the p53 pathway by inhibiting the binding of MDM2 and MDMX to p53. The development of WK298 benefited from a deep understanding of the key elements of the p53-MDM2/MDMX interaction structure .

HY-161040

MDM2-p53-IN-19	MDM-2/p53	Cancer
MDM2-p53-IN-19 (Compound A-8d) is a chemical intermediate that can be used to synthesize inhibitors of the *MDM2-p53* interaction with anticancer activity .

HY-158684

YX-02-030	PROTACs MDM-2/p53	Cancer
YX-02-030M is a PROTAC *MDM2* degrader. YX-02-030M inhibits MDM2-p53 binding and VHL-HIF1α binding with IC₅₀s of 63 nM and 1.35 μM respectively. YX-02-030M binds MDM2 and recruits the VHL E3 ubiquitin ligase to initiate MDM2 degradation, and effectively kills p53 mutant or deleted Triple-negative breast cancers (TNBC) cells. (Blue: VHL ligand; Black: linker; Pink: MDM2 inhibitor) .

HY-151171

MDM2/4-p53-IN-3	MDM-2/p53	Cancer
MDM2/4-p53-IN-3 is a *MDM2/4-p53* protein-protein interactions (PPIs) inhibitor (IC₅₀s: 18.5 nM for MDM2-p53, 14.8 nM for MDM4-p53). MDM2/4-p53-IN-3 can be used in the research of cancers, such as colon cancer .

HY-100892

MX69 2 Publications Verification	MDM-2/p53 IAP E1/E2/E3 Enzyme	Cancer
MX69 is an inhibitor of *MDM2/XIAP*, used for cancer treatment.

HY-18331

MI-219	MDM-2/p53	Cancer
MI-219 is an antagonist for *MDM2* with a K_i of 13.3 μM. MI-219 inhibits the *MDM2-p53* interaction, inhibits thus the proliferation of FSCCL cells, with an IC₅₀ of 2.5 μM .

HY-15676A

Idasanutlin (enantiomer) RG7388 (enantiomer)	MDM-2/p53 Drug Isomer Apoptosis	Cancer
Idasanutlin enantiomer is the isomer of Idasanutlin (HY-15676), and can be used as an experimental control. Idasanutlin (RG7388) is a potent and selective *MDM2* antagonist, inhibiting p53-MDM2 binding, with an IC₅₀ of 6 nM.

HY-15676R

Idasanutlin (Standard)	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Idasanutlin (Standard) is the analytical standard of Idasanutlin. This product is intended for research and analytical applications. Idasanutlin (RG7388) is a potent and selective MDM2 antagonist, inhibiting p53-MDM2 binding, with an IC50 of 6 nM.

HY-151169

MDM2/4-p53-IN-1	MDM-2/p53	Cancer
MDM2/4-p53-IN-1 is a potent *MDM2-p53* and MDM4-p53 inhibitor with IC₅₀ values of 35.9, 57.4 nM, respectively. MDM2/4-p53-IN-1 shows antiproliferative activity .

HY-152859

Brigimadlin BI 907828	E1/E2/E3 Enzyme MDM-2/p53	Cancer
Brigimadlin (BI 907828) is an orally active E3 ubiquitin-protein ligase *MDM-2* inhibitor, preventing MDM-2 from negatively regulating the tumor suppressor p53. Brigimadlin can be used for antineoplastic research .

HY-101518

Alrizomadlin 1 Publications Verification APG-115; AA-115	MDM-2/p53 E1/E2/E3 Enzyme Apoptosis	Cancer
Alrizomadlin (APG-115) is an orally active *MDM2* protein inhibitor binding to MDM2 protein with IC₅₀ and K_i values of 3.8 nM and 1 nM, respectively . Alrizomadlin blocks the interaction of MDM2 and p53 and induces cell-cycle arrest and apoptosis in a p53-dependent manner .

HY-112816

MA242	MDM-2/p53 Apoptosis	Cancer
MA242 is a specific dual inhibitor of *MDM2* and NFAT1. MA242 directly binds both MDM2 and NFAT1 with high affinity, induces their protein degradation, and inhibits NFAT1-mediated transcription of MDM2. MA242 induces apoptosis in pancreatic cancer cell lines regardless of p53 status .

HY-123544

RDR03871	MDM-2/p53	Cancer
RDR03871 (compound 2) is a potent dual *MDM2/MDM4* inhibitor with IC₅₀ values of 35.4 nM and 10.4 nM for MDM2-p53 and MDM4-p53, respectively .

HY-133760

MI-888	MDM-2/p53	Cancer
MI-888 is an orally active *MDM2* inhibitor with a K_i of 0.44 nM. MI-888 can inhibit the *MDM2-p53* interaction. MI-888 has favorable pharmacokinetic properties and anti-tumor activity .

HY-151170

MDM2/4-p53-IN-2	MDM-2/p53 Apoptosis	Cancer
MDM2/4-p53-IN-2 (2q) is a potent dual MDM2/ MDM4 inhibitor and p53 activator with the IC₅₀ values of 70.7 nM for MDM2- p53 and 81.4 nM for MDM4-p53 complexes. MDM2/4-p53-IN-2 regulates the cell cycle, induces cell apoptosis and has anticancer activity .

HY-50696

Nutlin-3 25+ Cited Publications	MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Nutlin-3 is a commercial available *p53-MDM2* inhibitor, with K_i of 90 nM.

HY-12296S

Navtemadlin-d7 AMG 232-d₇; KRT-232-d₇	Isotope-Labeled Compounds MDM-2/p53 E1/E2/E3 Enzyme	Cancer
Navtemadlin-d₇ is the deuterium labeled Navtemadlin. Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC₅₀ of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM .

Cat. No.	Product Name

HY-L109

Protein-protein Interaction Inhibitor Library

672 compounds

Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases, including cancer, infectious diseases, and neurodegenerative diseases. The classic drug targets are usually enzymes, ion channels, or receptors, the PPI indicate new potential therapeutic targets. Therefore, targeting PPI is a new direction in treating diseases and an essential strategy for the development of new drugs.

However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.

With the development of high-throughput technology, high-throughput screening is also gradually used for the identification of PPI inhibitors, but the compound library used for conventional target screening is not very effective in screening PPI inhibitors. To improve screening efficiency, MCE carefully selected 672 PPI inhibitors and mainly targeting MDM2-p53, Keap1-Nrf2, PD-1/PD-L1, Myc-Max, etc. MCE Protein-protein Interaction Inhibitor Library is a useful tool for PPI drug discovery and related research.

HY-L128

E3 Ligase Ligand Library

88 compounds

Proteolysis-targeting chimera (PROTAC) has been developed to be a useful technology for targeted protein degradation. PROTACs consist of a ligand for E3 ligase (E3 ligase binder), a linker and a ligand (mostly small-molecule inhibitor) for protein of interest（target binder）. Upon binding to the target protein, the PROTACs can recruit E3 for target protein ubiquitination, which is subjected to proteasome-mediated degradation.

Although there are more than 600 E3 ubiquitin ligases, only several with small molecule ligands have been used for designing PROTACs, including Skp1-Cullin-F box complex containing Hrt1 (SCF), Von Hippel-Lindau tumor suppressor (VHL), Cereblon (CRBN), inhibitor of apoptosis proteins (IAPs), and mouse double minute 2 homolog (MDM2).

MCE carefully prepared a unique collection of 88 ligands for E3 ligase, which have been reported to be used in PROTAC design. MCE E3 ligase ligand library is a useful tool for PROTAC development.

Cat. No.	Product Name	Type

HY-W008907

5'-O-Tritylthymidine 5-OTT	Gene Sequencing and Synthesis
5'-O-Tritylthymidine is an inhibitor of TK-2 and inhibits angiogenesis . 5'-O-Tritylthymidine targets FAK-Mdm-2 interactions, decreasing cell viability and increasing apoptosis.

Cat. No.	Product Name	Target	Research Area

HY-P4210

Sulanemadlin ALRN-6924; MP-4897	MDM-2/p53	Cancer
Sulanemadlin (ALRN-6924) is a potent and cell-permeating p53-based peptidomimetic macrocycles. Sulanemadlin is a inhibitor of the p53-MDM2, p53-MDMX, or both p53 and MDM2 and MDMX protein-protein interactions. Sulanemadlin can be used for cancers research .

HY-106263B

Tyroserleutide hydrochloride	PTEN PDK-1 MDM-2/p53 Apoptosis Akt	Cancer
Tyroserleutide hydrochloride is a tripeptide isolated from the degradation products of porcine spleen with antitumor activity. Tyroserleutide hydrochloride can upregulate the expression of the tumor suppressor gene PTEN and inhibit the activity of AKT and PDK1. Tyroserleutide hydrochloride inhibits tumor cell proliferation and MDM2 phosphorylation by inhibiting the PI3K/AKT pathway, and also upregulates P21, P27, P53, and induces mitochondrial damage and cell apoptosis .

HY-141584

ATSP-7041	MDM-2/p53	Cancer
ATSP-7041, a selective dual peptide inhibitor of *MDM2* and MDMX, effectively reactivates the p53 tumor suppressor pathway in a mechanism-dependent manner in p53-positive cancers .

HY-P10914

D-CopA3	MDM-2/p53 Autophagy	Inflammation/Immunology Cancer
D-CopA3 is the inhibitor for *MDM2* and the activator for p53 signaling pathway. D-CopA3 exhibits cytotoxicity in colorectal cancer cells HCT-116, LoVo, and RKO (IC₅₀=15-18 μM), induces JNK/Beclin-1 mediated autophagy. D-CopA3 downregulates the expression of cell cycle inhibitory protein p21Cip1/Waf1, enhances the mucosal barrier function and reduces penetration of inflammatory mediators. D-CopA3 exhibits anti-inflammtory activity in mouse C. difficile toxin A-induced acute enteritis models and DSS (HY-116282)-induced chronic colitis models. D-CopA3 exhibits antitumor efficacy in mouse HCT-116 xenograft models .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0068

Solasodine 4 Publications Verification Purapuridine; Solancarpidine; Solasodin	Cardiovascular Disease Structural Classification Neurological Disease Classification of Application Fields Source classification Plants Infection Alkaloids Piperidine Alkaloids Solanum nigrum Linn. Solanaceae Inflammation/Immunology Disease Research Fields	MDM-2/p53 Fungal E1/E2/E3 Enzyme Apoptosis
Solasodine (Purapuridine) is a steroidal alkaloid that occurs in plants of the Solanaceae family. Solasodine induces apoptosis by inhibiting the *p53-MDM2* complex**, p21Waf1/Cip1, and Bcl-2 proteins. Solasodine has neuroprotective, antifungal, hypotensive, anticancer, antiatherosclerotic, antiandrogenic and anti-inflammatory activities .

HY-N7012

7,3',4'-Tri-O-methylluteolin 1 Publications Verification 5-Hydroxy-3',4',7-trimethoxyflavone	Structural Classification Monophenols Flavonoids Classification of Application Fields Flavones Labiatae Source classification Phenols Plants Swartzia polyphylla DC. Inflammation/Immunology Disease Research Fields	Lipoxygenase TNF Receptor Interleukin Related COX Fungal Parasite Apoptosis
7,3',4'-Tri-O-methylluteolin (5-Hydroxy-3',4',7-trimethoxyflavone) is a flavonoid with multiple biological activities. 7,3',4'-Tri-O-methylluteolin inhibits soybean lipoxygenase (LOX), with an IC₅₀ value of 23.97 µg/mL. 7,3',4'-Tri-O-methylluteolin possesses anti-inflammatory effects in Lipopolysaccharides (HY-D1056) (LPS)-induced RAW 264.7 macrophages. 7,3',4'-Tri-O-methylluteolin inhibits the binding of MDM2 with p53 and induces apoptosis in MCF-7 breast cancer cells. 7,3',4'-Tri-O-methylluteolin also has antioxidant, antifungal and antitrypanosomal activities sup>[4]sup>[5].

Cat. No.	Product Name	Chemical Structure

HY-153939S

Idasanutlin-d3-1
Idasanutlin-d₃-1 (RG7388-d₃-1) is the deuterium labeled Idasanutlin. Idasanutlin is a potent antagonist of *MDM2/p53*. Idasanutlin inhibits relapsed or refractory acute myeloid leukemia .

HY-12296S

Navtemadlin-d7
Navtemadlin-d₇ is the deuterium labeled Navtemadlin. Navtemadlin (AMG 232) is a potent, selective and orally available inhibitor of p53-MDM2 interaction, with an IC₅₀ of 0.6 nM. Navtemadlin binds to MDM2 with a Kd of 0.045 nM .

HY-18986S

SAR405838-d10
SAR405838-d₁₀ (MI-77301-d₁₀) is the deuterium labeled SAR405838 (HY-18986). SAR405838 (MI-77301), an analog of MI-773, is a highly potent and selective *MDM2-p53* interaction inhibitor. SAR405838 binds to MDM2 with a K_i of 0.88 nM. SAR405838 induces apoptosis and has potent antitumor activity .

HY-W704348

Diphenyltin Dichloride-d10
Diphenyltin Dichloride-d₁₀ is the deuterium labeled NSC405640 (HY-144105). NSC405640 is a potent inhibitor of the MDM2-p53 interaction. NSC405640 rescues structural p53 mutations. NSC405640 selectively inhibits the growth of cell lines with wild-type p53 .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks